Table 1.
Three risk groups corresponding to the different strategies of CNS-targeted therapy, based on actualized or unfulfilled CNS prophylaxis
| Prophylaxis group | CNS prophylaxis regimen | R-CHOP | R-CEOP | R-CHOEP | |
|---|---|---|---|---|---|
|
Intravenous HD-MTX |
Intrathecal MTX |
||||
| 1 (n = 43) | 3–5 g/m2 × 2–3 | 12.5 mg × 2–3 | 10 | 13 | 20 |
| 2 (n = 14) | 1–3 g/m2 × 1–3 | 12.5 mg × 1–3 | 1 | 11 | 2 |
| 3 (n = 38) | None | None | 16 | 19 | 3 |
| Median number of cycles (and range) | 7 (6–8) | 6 (1–8) | 7 (5–9) |
R-CHOP, rituximab-cyclophosamide-doxorubicin-vincristine-prednisone; R-CEOP, rituximab-cyclophosamide-epirubicin-prednisone; R-CHOEP, rituximab-cyclophosamide-doxorubicin-vincristine-etoposide-prednisone